Skip to main content
Top
Published in: Molecular Cancer 1/2009

Open Access 01-12-2009 | Research

Inhibition of HIF-1alpha activity by homeodomain-interacting protein kinase-2 correlates with sensitization of chemoresistant cells to undergo apoptosis

Authors: Lavinia Nardinocchi, Rosa Puca, Ada Sacchi, Gabriella D'Orazi

Published in: Molecular Cancer | Issue 1/2009

Login to get access

Abstract

Background

Homeodomain-interacting protein kinase-2 (HIPK2), a transcriptional co-repressor with apoptotic function, can affect hypoxia-inducible factor 1 (HIF-1) transcriptional activity, through downmodulation of its HIF-1α subunit, in normoxic condition. Under hypoxia, a condition often found in solid tumors, HIF-1α is activated to induce target genes involved in chemoresistance, inhibition of apoptosis and tumor progression. Here, we investigated whether the HIPK2 overexpression could downregulate HIF-1α expression and activity in tumor cells treated with hypoxia-mimicking condition, and evaluated whether HIPK2-dependent downregulation of HIF-1α could sensitize chemoresistant tumor cells to adriamycin (ADR)-induced apoptosis.

Methods

Tumor cell lines carrying wild-type p53, siRNA p53, or mutant p53 were overexpressed with HIPK2 (full length or catalytic inactive mutant) and treated with cobalt chloride (CoCl2) to mimic hypoxia, in the presence or absence of ADR treatment. HIF-1α expression was measured by semiquantitative reverse-transcriptase (RT)-PCR and Western immunoblotting and HIF-1 activity was evaluated by luciferase assay using reporter plasmid containing hypoxia response elements (HREs) upstream of luciferase gene. HIF-1 target genes, including multidrug resistance 1 (MDR1) and the antiapoptotic Bcl2 were determined by RT-PCR. Cell survival and apoptosis were measured by colony assay and cleavage of the caspase-3 substrate PARP, respectively.

Results

Overexpression of HIPK2 resulted in downmodulation of cobalt-stabilized HIF-1α protein and HIF-1α mRNA levels, with subsequent inhibition of HIF-1 transcriptional activity. MDR1 and Bcl-2 gene expression was downmodulated by HIPK2 overexpression in cobalt-treated cells. Inhibition of HIF-1 transcriptional activity was dependent on HIPK2 catalytic activity. HIPK2 overexpression did not induce per se apoptosis of cobalt-treated cells, on the contrary it sensitized cobalt-treated cells to ADR-induced apoptosis, regardless of their p53 status.

Conclusion

The ability of HIPK2 to restore the apoptosis-inducing potential of chemotherapeutic drug in hypoxia-mimicking condition and therefore to sensitize chemoresistant tumor cells suggests that HIPK2 may induce fundamental alterations in cell signaling pathways, involving or not p53 function. Thus potential use of HIPK2 is promising for cancer treatment by potentiating cytotoxic therapies, regardless of p53 cell status.
Appendix
Available only for authorised users
Literature
1.
go back to reference Kim YH, Choi CY, Lee SJ, Conti MA, Kim Y: Homeodomain-interacting protein kinases, a novel family of co-repressors for homeodomain transcription factors. J Biol Chem. 1998, 273: 25875-25879. 10.1074/jbc.273.40.25875CrossRefPubMed Kim YH, Choi CY, Lee SJ, Conti MA, Kim Y: Homeodomain-interacting protein kinases, a novel family of co-repressors for homeodomain transcription factors. J Biol Chem. 1998, 273: 25875-25879. 10.1074/jbc.273.40.25875CrossRefPubMed
2.
go back to reference D'Orazi G, Cecchinelli B, Bruno T, Manni I, Higashimoto Y, Saito S, Gostissa M, Coen S, Marchetti A, Del Sal G, Piaggio G, Fanciulli M, Appella E, Soddu S: Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis. Nature Cell Biol. 2002, 4: 11-19. 10.1038/ncb714CrossRefPubMed D'Orazi G, Cecchinelli B, Bruno T, Manni I, Higashimoto Y, Saito S, Gostissa M, Coen S, Marchetti A, Del Sal G, Piaggio G, Fanciulli M, Appella E, Soddu S: Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis. Nature Cell Biol. 2002, 4: 11-19. 10.1038/ncb714CrossRefPubMed
3.
go back to reference Hofmann TG, Moller A, Sirma H, Zebtgraft H, Taya Y, Droge W, Will H, Schmitz ML: Regulation of p53 activity by its interaction with homeodomain-interacting protein kinase-2. Nauret Cell Biol. 2002, 4: 1-10. 10.1038/ncb715. 10.1038/ncb715CrossRef Hofmann TG, Moller A, Sirma H, Zebtgraft H, Taya Y, Droge W, Will H, Schmitz ML: Regulation of p53 activity by its interaction with homeodomain-interacting protein kinase-2. Nauret Cell Biol. 2002, 4: 1-10. 10.1038/ncb715. 10.1038/ncb715CrossRef
4.
go back to reference Puca R, Nardinocchi L, Gal H, Rechavi G, Amariglio N, Domany E, Notterman DA, Scarsella M, Leonetti C, Sacchi A, Blandino G, Givol D, D'Orazi G: Reversible dysfunction of wild-type p53 following homeodomain-interacting protein kinase-2 knockdown. Cancer Res. 2008, 68: 3707-3714. 10.1158/0008-5472.CAN-07-6776CrossRefPubMed Puca R, Nardinocchi L, Gal H, Rechavi G, Amariglio N, Domany E, Notterman DA, Scarsella M, Leonetti C, Sacchi A, Blandino G, Givol D, D'Orazi G: Reversible dysfunction of wild-type p53 following homeodomain-interacting protein kinase-2 knockdown. Cancer Res. 2008, 68: 3707-3714. 10.1158/0008-5472.CAN-07-6776CrossRefPubMed
5.
go back to reference Di Stefano V, Rinaldo C, Sacchi A, Soddu S, D'Orazi G: Homeodomain-interacting protein kinase-2 activity and p53 phosphorylation are critical events for cisplatin-mediated apoptosis. Exp Cell Res. 2004, 293: 311-320. 10.1016/j.yexcr.2003.09.032CrossRefPubMed Di Stefano V, Rinaldo C, Sacchi A, Soddu S, D'Orazi G: Homeodomain-interacting protein kinase-2 activity and p53 phosphorylation are critical events for cisplatin-mediated apoptosis. Exp Cell Res. 2004, 293: 311-320. 10.1016/j.yexcr.2003.09.032CrossRefPubMed
6.
go back to reference Nardinocchi L, Puca R, Sacchi A, D'Orazi G: HIPK2 knock-down compromises tumor cell efficiency to repair damaged DNA. Biochem Biophys Res Commun. 2007, 361: 249-255. 10.1016/j.bbrc.2007.07.031CrossRefPubMed Nardinocchi L, Puca R, Sacchi A, D'Orazi G: HIPK2 knock-down compromises tumor cell efficiency to repair damaged DNA. Biochem Biophys Res Commun. 2007, 361: 249-255. 10.1016/j.bbrc.2007.07.031CrossRefPubMed
7.
go back to reference Puca R, Nardinocchi L, Pistritto G, D'Orazi G: Overexpression of HIPK2 circumvents the blockade of apoptosis in chemoresistant ovarian cancer cells. Gynecol Oncol. 2008, 109: 403-410. 10.1016/j.ygyno.2008.02.018CrossRefPubMed Puca R, Nardinocchi L, Pistritto G, D'Orazi G: Overexpression of HIPK2 circumvents the blockade of apoptosis in chemoresistant ovarian cancer cells. Gynecol Oncol. 2008, 109: 403-410. 10.1016/j.ygyno.2008.02.018CrossRefPubMed
8.
go back to reference D'Orazi G, Sciulli MG, Di Stefano V, Riccioni S, Frattini M, Falcioni R, Bertario L, Sacchi A, Patrignani P: Homeodomain-interacting protein kinase-2 restrains cytosolic-phospholipase-A2-dependent prostaglandin-E2 generation in human colorectal cancer cells. Clin Cancer Res. 2006, 12: 735-741. 10.1158/1078-0432.CCR-05-1557CrossRefPubMed D'Orazi G, Sciulli MG, Di Stefano V, Riccioni S, Frattini M, Falcioni R, Bertario L, Sacchi A, Patrignani P: Homeodomain-interacting protein kinase-2 restrains cytosolic-phospholipase-A2-dependent prostaglandin-E2 generation in human colorectal cancer cells. Clin Cancer Res. 2006, 12: 735-741. 10.1158/1078-0432.CCR-05-1557CrossRefPubMed
9.
go back to reference Nardinocchi L, Puca R, Guidolin D, Belloni AS, Bossi G, Michiels C, Sacchi A, Onisto M, D'Orazi G: Trancriptional regulation of hypoxia-inducible factor 1alpha by HIPK2 suggests a novel mechanism to restrain tumor growth. BBA Mol Cell Res. 2008, DOI:10.1016/j.bbamcr.2008.10.013. Nardinocchi L, Puca R, Guidolin D, Belloni AS, Bossi G, Michiels C, Sacchi A, Onisto M, D'Orazi G: Trancriptional regulation of hypoxia-inducible factor 1alpha by HIPK2 suggests a novel mechanism to restrain tumor growth. BBA Mol Cell Res. 2008, DOI:10.1016/j.bbamcr.2008.10.013.
10.
go back to reference Puca R, Nardinocchi L, D'Orazi G: Regulation of vascular endothelial growth factor expression ny homeodomain-interacting protein kinase-2. J Exp Clin Cancer Res. 2008, 27: 22- 10.1186/1756-9966-27-22PubMedCentralCrossRefPubMed Puca R, Nardinocchi L, D'Orazi G: Regulation of vascular endothelial growth factor expression ny homeodomain-interacting protein kinase-2. J Exp Clin Cancer Res. 2008, 27: 22- 10.1186/1756-9966-27-22PubMedCentralCrossRefPubMed
11.
go back to reference Semenza GL: Involvement of hypoxia-inducible factor 1 in human cancer. Nature Rev Cancer. 2003, 3: 721-732. 10.1038/nrc1187.CrossRef Semenza GL: Involvement of hypoxia-inducible factor 1 in human cancer. Nature Rev Cancer. 2003, 3: 721-732. 10.1038/nrc1187.CrossRef
12.
go back to reference Wang GL, Jiang B-H, Rue EA, Semenza GL: Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA. 1995, 92: 5510-5514. 10.1073/pnas.92.12.5510PubMedCentralCrossRefPubMed Wang GL, Jiang B-H, Rue EA, Semenza GL: Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA. 1995, 92: 5510-5514. 10.1073/pnas.92.12.5510PubMedCentralCrossRefPubMed
13.
go back to reference Jiang BH, Semenza GL, Bauer H, Marti H: Hypoxia-inducible factor 1 levels vary exponentially over a physiologically relevant range of O2 tension. Am J Physiol. 1996, 271: C1172-C1180.PubMed Jiang BH, Semenza GL, Bauer H, Marti H: Hypoxia-inducible factor 1 levels vary exponentially over a physiologically relevant range of O2 tension. Am J Physiol. 1996, 271: C1172-C1180.PubMed
14.
go back to reference Liu L, Ning X, Sun L, Zhang H, Shi Y, Guo C, Han S, Liu J, Sun S, Han Z, Wu K, Fan D: Hypoxia-inducible factor-1a contributes to hypoxia-induced chemoresistance in gastric cancer. Cancer Sci. 2008, 99: 121-128.PubMed Liu L, Ning X, Sun L, Zhang H, Shi Y, Guo C, Han S, Liu J, Sun S, Han Z, Wu K, Fan D: Hypoxia-inducible factor-1a contributes to hypoxia-induced chemoresistance in gastric cancer. Cancer Sci. 2008, 99: 121-128.PubMed
15.
go back to reference Huang LE, Arany Z, Livingston DM, Bunn HF: Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its α subunit. J Biol Chem. 1996, 271: 32253-32259. 10.1074/jbc.271.50.32253CrossRefPubMed Huang LE, Arany Z, Livingston DM, Bunn HF: Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its α subunit. J Biol Chem. 1996, 271: 32253-32259. 10.1074/jbc.271.50.32253CrossRefPubMed
16.
go back to reference Wang GL, Semenza GL: General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc Natl Acad Sci USA. 1993, 90: 4304-4308. 10.1073/pnas.90.9.4304PubMedCentralCrossRefPubMed Wang GL, Semenza GL: General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc Natl Acad Sci USA. 1993, 90: 4304-4308. 10.1073/pnas.90.9.4304PubMedCentralCrossRefPubMed
18.
go back to reference Greijer AE, Wall van der E: The role of hypoxia inducible factor 1 (HIF-1) in hypoxia induced apoptosis. J Clin Pathol. 2004, 57: 1009-1014. 10.1136/jcp.2003.015032PubMedCentralCrossRefPubMed Greijer AE, Wall van der E: The role of hypoxia inducible factor 1 (HIF-1) in hypoxia induced apoptosis. J Clin Pathol. 2004, 57: 1009-1014. 10.1136/jcp.2003.015032PubMedCentralCrossRefPubMed
19.
go back to reference Borst P, Jankers J, Rottenberg S: What makes tumors multidrug resistant?. Cell Cycle. 2007, 22: 2782-2787.CrossRef Borst P, Jankers J, Rottenberg S: What makes tumors multidrug resistant?. Cell Cycle. 2007, 22: 2782-2787.CrossRef
20.
go back to reference Fardel O, Lecureur V, Guillouzo A: The P-glicoprotein multidrug transporter. Gen Pharmacol. 1996, 27: 1283-1291.CrossRefPubMed Fardel O, Lecureur V, Guillouzo A: The P-glicoprotein multidrug transporter. Gen Pharmacol. 1996, 27: 1283-1291.CrossRefPubMed
21.
go back to reference Comerford KM, Wallace TJ, Karhnausen J, Louis NA, Montalto MC, Colgan SP: Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res. 2002, 62: 3387-3394.PubMed Comerford KM, Wallace TJ, Karhnausen J, Louis NA, Montalto MC, Colgan SP: Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res. 2002, 62: 3387-3394.PubMed
22.
go back to reference Talks KL, Turley H, Gatter KC, Maxwell PH, Pugh CW, Ratcliff PJ, Harris AL: The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol. 2000, 157: 411-421.PubMedCentralCrossRefPubMed Talks KL, Turley H, Gatter KC, Maxwell PH, Pugh CW, Ratcliff PJ, Harris AL: The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol. 2000, 157: 411-421.PubMedCentralCrossRefPubMed
23.
go back to reference Zhang Q, Yoshimatsu Y, Hildebrabd J, Frisch SM, Goodman RH: Homeodomain interacting protein kinase 2 promotes apoptosis by downregulating the transcriptional corepressor CtBP. Cell. 2003, 115: 177-186. 10.1016/S0092-8674(03)00802-XCrossRefPubMed Zhang Q, Yoshimatsu Y, Hildebrabd J, Frisch SM, Goodman RH: Homeodomain interacting protein kinase 2 promotes apoptosis by downregulating the transcriptional corepressor CtBP. Cell. 2003, 115: 177-186. 10.1016/S0092-8674(03)00802-XCrossRefPubMed
24.
go back to reference Hofmann TG, Stollberg N, Schmitz ML, Will H: HIPK2 regulates transforming growth factor-beta-induced c-Jun NH(2)-terminal kinase activation and apoptosis in human hepatoma cells. Cancer Res. 2003, 63: 8781-8787. Hofmann TG, Stollberg N, Schmitz ML, Will H: HIPK2 regulates transforming growth factor-beta-induced c-Jun NH(2)-terminal kinase activation and apoptosis in human hepatoma cells. Cancer Res. 2003, 63: 8781-8787.
25.
go back to reference Doxakis E, Huang EJ, Davies AM: Homeodomain-interacting protein kinase-2 regulates apoptosis in developing sensory and sympathetic neurons. Curr Biol. 2004, 14: 1761-165. 10.1016/j.cub.2004.09.050CrossRefPubMed Doxakis E, Huang EJ, Davies AM: Homeodomain-interacting protein kinase-2 regulates apoptosis in developing sensory and sympathetic neurons. Curr Biol. 2004, 14: 1761-165. 10.1016/j.cub.2004.09.050CrossRefPubMed
26.
go back to reference Unruh A, Ressel A, Mohamed HG, Johnson RS, Nadrowitz R, Richter E, Katschinski DM, Wenger RH: The hypoxia-inducible factor-1α is a negative factor for tumor therapy. Oncogene. 2003, 22: 3213-3220. 10.1038/sj.onc.1206385CrossRefPubMed Unruh A, Ressel A, Mohamed HG, Johnson RS, Nadrowitz R, Richter E, Katschinski DM, Wenger RH: The hypoxia-inducible factor-1α is a negative factor for tumor therapy. Oncogene. 2003, 22: 3213-3220. 10.1038/sj.onc.1206385CrossRefPubMed
27.
go back to reference Chen P, Iavarone A, Fick J, Edwards M, Prados M, Israel MA: Constitutional p53 mutations associated with brain tumors in young adults. Cancer Genetics and Cytogenetics. 1995, 2: 106-115. 10.1016/0165-4608(94)00213-U.CrossRef Chen P, Iavarone A, Fick J, Edwards M, Prados M, Israel MA: Constitutional p53 mutations associated with brain tumors in young adults. Cancer Genetics and Cytogenetics. 1995, 2: 106-115. 10.1016/0165-4608(94)00213-U.CrossRef
28.
go back to reference Di Stefano V, Mattiussi M, Sacchi A, D'Orazi G: HIPK2 inhibits both MDM2 gene and protein by, respectively, p53-dependent and independent regulations. FEBS Lett. 2005, 579: 5473-5480. 10.1016/j.febslet.2005.09.008CrossRefPubMed Di Stefano V, Mattiussi M, Sacchi A, D'Orazi G: HIPK2 inhibits both MDM2 gene and protein by, respectively, p53-dependent and independent regulations. FEBS Lett. 2005, 579: 5473-5480. 10.1016/j.febslet.2005.09.008CrossRefPubMed
Metadata
Title
Inhibition of HIF-1alpha activity by homeodomain-interacting protein kinase-2 correlates with sensitization of chemoresistant cells to undergo apoptosis
Authors
Lavinia Nardinocchi
Rosa Puca
Ada Sacchi
Gabriella D'Orazi
Publication date
01-12-2009
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2009
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-8-1

Other articles of this Issue 1/2009

Molecular Cancer 1/2009 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine